On July 24, 2026, a clinical trial titled "Determination of Resistance Training Status for Patients on Glucagon-Like Peptide-1 Receptor Agonists" was listed as recruiting. The trial, registered as NCT07702461, involves patients taking GLP-1 receptor agonists, a drug class that includes exenatide, which is an approved medication.
The study's current status is recruiting, according to the trial registry. No phase has been specified for this trial in the available data.
The trial title indicates a focus on determining resistance training status among patients using this class of medications. No results, outcomes, or findings have been posted at this time. The event data does not include information about the trial's design, endpoints, or projected completion date.
As the trial is in the recruiting stage, no conclusions can be drawn about outcomes at this point. Further updates may be available as the trial progresses through its stages.
Readers interested in learning more about exenatide, including its approved uses and background, can refer to the compound overview for additional context.